Month: April 2023
Excerpt from the Press Release: Carlsbad, CA and Shanghai, China, April 05, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced today that its development partner Newsoara Biopharma Co. Ltd, has enrolled the first patient in its ongoing Phase 3…
Read More
Excerpt from the Press Release: MELBOURNE, Australia and SAN FRANCISCO, April 04, 2023 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the first participant has been dosed in the United Kingdom in the Company’s Phase 2…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vega Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies for rare blood disorders, today announced that its clinical trial program for VGA039 has been initiated. The first subject has been dosed in the Phase 1 study of VGA039 (NCT05776069), a multinational clinical trial being…
Read More
Excerpt from the Press Release: SAN JOSE, Calif., April 5, 2023 /PRNewswire/ — MAPS Public Benefit Corporation (“MAPS PBC”), a clinical-stage company dedicated to changing the way mental health conditions are treated, announced positive topline results from an observational follow-up study evaluating the long-term safety and efficacy of MDMA-assisted therapy for post–traumatic stress disorder (“PTSD”). Preliminary findings…
Read More
Excerpt from the Press Release: SAN FRANCISCO and TORONTO and ZÜRICH, Switzerland, April 05, 2023 (GLOBE NEWSWIRE) — Endogena Therapeutics Inc., a clinical-stage biotech company focused on the development of endogenous regenerative medicines, announced today that the dose-escalation stage of its phase 1/2a study of EA-2353 in retinitis pigmentosa (RP) has been successfully completed. No…
Read More
Excerpt from the Press Release: CONCORD, Mass., March 30, 2023 /PRNewswire/ — Comanche Biopharma Corp., a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for Comanche’s novel, siRNA therapy to treat preeclampsia. Preeclampsia is a prevalent hypertensive disorder of pregnancy for which there…
Read More
— Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by 2025 — — The Nine Incremental Serotypes in VAX-24 Cover an Additional 20-25 Percent of Strains Causing Invasive Pneumococcal Disease Over the Current Standard-of-Care PCV in Infants — Excerpt from the Press Release: SAN CARLOS, Calif., March 30, 2023…
Read More
Peptide-level insights from deep, unbiased proteomics enable protein variant analysis of patient samples, revealing potential non-small cell lung cancer biomarkers Excerpt from the Press Release: REDWOOD CITY, Calif., March 29, 2023 (GLOBE NEWSWIRE) — Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced a new scientific publication…
Read More
Bigfoot strengthens its technology portfolio, enhancing the company’s ability to deliver on its mission to reduce the burden of diabetes for people who require insulin Excerpt from the Press Release: MILPITAS, Calif.–(BUSINESS WIRE)–Bigfoot Biomedical (Bigfoot), a leader in developing intelligent connected injection support systems, today announced the acquisition of a reinforcement learning algorithm for the…
Read More
The planned Phase 3 program consists of three trials, SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes to evaluate the safety and efficacy of efruxifermin (EFX) in patients with NASH SYNCHRONY Histology and SYNCHRONY Real-World are expected to begin enrollment in the second half of this year Consistent with the encouraging clinical profile to date reported…
Read More- « Previous
- 1
- 2
- 3
- Next »